SCT650C
Phase 2Small molecule
SCT650C is one of 77 small molecule programs targeting Arthritis. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Simponi
Johnson & JohnsonPhase 3
Taltz
Eli LillyPhase 3
Aleve
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Ilaris
NovartisPhase 3
Remicade
OOrganon and Co
Phase 3
Kenalog
BBassett Healthcare
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hidradenitis Suppurativa1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCT650C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSinocelltech Ltd.